Please login to the form below

Not currently logged in

Otsuka in-licenses leukaemia biologic for USD 200m

Otsuka buys the North American rights to PDL Biopharma's leukaemia drug, IV Busulfex, for USD 200m in cash to boost its global cancer franchise

Privately held Japanese pharmaceutical company Otsuka has agreed to buy North American rights to US biopharmaceutical company PDL Biopharma's leukaemia drug, IV Busulfex, for USD 200m in cash to boost its global cancer franchise.

Otsuka and PDL will complete the transaction by March 2008, according to a joint statement release on 17 December. PDL's partners will keep the rights to sell the medicine outside of North America, according to the statement.

IV Busulfex is already sold in more than 40 countries, but Otsuka wants to develop the drug for wider use in the important US market.

PDL revealed in October 2007 that it would sell itself entirely or its key assets.

The financial advisor to Otsuka in the transaction was Montgomery & Co, while PDL was advised by Merrill Lynch & Co.

19th December 2007


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...